Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene

T. J. Wiktor, R. I. Macfarlan, K. J. Reagan, B. Dietzschold, P. J. Curtis, W. H. Wunner, M. P. Kieny, R. Lathe, J. P. Lecocq, M. Mackett

Research output: Contribution to journalArticlepeer-review


Inoculation of rabbits and mice with a vaccinia-rabies glycoprotein recombinant (V-RG) virus resulted in rapid induction of high concentrations of rabies virus-neutralizing antibodies and protection from severe intracerebral challenge with several strains of rabies virus. Protection from virus challenge also was achieved against the rabies-related Duvenhage virus but not against the Mokola virus. Effective immunization by V-RG depended on the expression of a rabies glycoprotein that registered proline rather than leucine as the eighth amino acid from its NH2 terminus (V-RGpro8). A minimum dose required for effective immunization of mice was 104 plaque-forming units of V-RGpro8 virus. β-propiolactone-inactivated preparations of V-RGpro8 virus also induced high levels of rabies virus-neutralizing antibody and protected mice against intracerebral challenge with street rabies virus. V-RGpro8 virus was highly effective in priming mice to generate a secondary rabies virus-specific cytotoxic T-lymphocyte response following culture of lymphocytes with either ERA or PM strains of rabies virus.

Original languageEnglish
Pages (from-to)7194-7198
Number of pages5
JournalProceedings of the National Academy of Sciences (PNAS)
Issue number22 I
Publication statusPublished - 1984


Dive into the research topics of 'Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene'. Together they form a unique fingerprint.

Cite this